Skip to main content

Endothelial progenitor cell therapy for atherosclerosis: the philosopher's stone for an aging population?

Publication ,  Journal Article
Kravchenko, J; Goldschmidt-Clermont, PJ; Powell, T; Stallard, E; Akushevich, I; Cuffe, MS; Manton, KG
Published in: Sci Aging Knowledge Environ
June 22, 2005

Much of the increased risk for atherosclerosis progression with age may be a result of age-related declines in the capacity of precursor cells to repair damage in the arterial endothelium. To estimate the impact of progenitor cell therapy for atherosclerosis on cardiovascular disease (CVD) mortality, life expectancy, and survival, as compared with the lifetime control of conventional risk factors, we modeled the health effects of bone marrow-derived endothelial progenitor cell therapy using data from the 1950 to 1996 follow-up of the Framingham Heart Study. To model cardiovascular disease mortality, we assumed that progenitor cell therapy was applied at age 30, with the effect assumed to be a 10-year delay in atherosclerosis progression. Age projections were constructed analytically using the stochastic process model for risk factor dynamics and mortality and microsimulation techniques. We considered three types of interventions: (i) keeping risk factors within selected limits to model current clinical recommendations; (ii) an age shift of 10 years to model the effects of progenitor cell therapy; and (iii) elimination of a competing risk (such as cancer). Our study suggests that progenitor cell therapy might increase life expectancy in the population as much as the complete elimination of cancer (in females, an additional 3.67 versus 3.37 years; in males, an additional 5.94 versus 2.86 years, respectively).

Duke Scholars

Published In

Sci Aging Knowledge Environ

DOI

EISSN

1539-6150

Publication Date

June 22, 2005

Volume

2005

Issue

25

Start / End Page

pe18

Location

United States

Related Subject Headings

  • Stem Cell Transplantation
  • Risk Factors
  • Models, Theoretical
  • Middle Aged
  • Life Expectancy
  • Humans
  • Endothelial Cells
  • Disease Progression
  • Case-Control Studies
  • Cardiovascular Diseases
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kravchenko, J., Goldschmidt-Clermont, P. J., Powell, T., Stallard, E., Akushevich, I., Cuffe, M. S., & Manton, K. G. (2005). Endothelial progenitor cell therapy for atherosclerosis: the philosopher's stone for an aging population? Sci Aging Knowledge Environ, 2005(25), pe18. https://doi.org/10.1126/sageke.2005.25.pe18
Kravchenko, Julia, Pascal J. Goldschmidt-Clermont, Tiffany Powell, Eric Stallard, Igor Akushevich, Michael S. Cuffe, and Kenneth G. Manton. “Endothelial progenitor cell therapy for atherosclerosis: the philosopher's stone for an aging population?Sci Aging Knowledge Environ 2005, no. 25 (June 22, 2005): pe18. https://doi.org/10.1126/sageke.2005.25.pe18.
Kravchenko J, Goldschmidt-Clermont PJ, Powell T, Stallard E, Akushevich I, Cuffe MS, et al. Endothelial progenitor cell therapy for atherosclerosis: the philosopher's stone for an aging population? Sci Aging Knowledge Environ. 2005 Jun 22;2005(25):pe18.
Kravchenko, Julia, et al. “Endothelial progenitor cell therapy for atherosclerosis: the philosopher's stone for an aging population?Sci Aging Knowledge Environ, vol. 2005, no. 25, June 2005, p. pe18. Pubmed, doi:10.1126/sageke.2005.25.pe18.
Kravchenko J, Goldschmidt-Clermont PJ, Powell T, Stallard E, Akushevich I, Cuffe MS, Manton KG. Endothelial progenitor cell therapy for atherosclerosis: the philosopher's stone for an aging population? Sci Aging Knowledge Environ. 2005 Jun 22;2005(25):pe18.

Published In

Sci Aging Knowledge Environ

DOI

EISSN

1539-6150

Publication Date

June 22, 2005

Volume

2005

Issue

25

Start / End Page

pe18

Location

United States

Related Subject Headings

  • Stem Cell Transplantation
  • Risk Factors
  • Models, Theoretical
  • Middle Aged
  • Life Expectancy
  • Humans
  • Endothelial Cells
  • Disease Progression
  • Case-Control Studies
  • Cardiovascular Diseases